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ABSTRACT
Background: Exacerbations of bronchial asthma usually occur in the autumn. To our knowledge, however,
the effectiveness of drugs for preventing exacerbations of asthma in the autumn has not been studied previ-
ously, except for leukotriene receptor antagonists and Omalizmab.
Methods: This study compared the prophylactic effectiveness of suplatast tosilate with that of mequitazine in
children with asthma symptoms, which is usually exacerbated in the autumn. The study group comprised 27
children aged 2 to 15 years who required treatment for asthmatic attacks during the past year and tested posi-
tive at least for mite allergen in the preceding autumn. The subjects were randomly assigned to receive either
suplatast or mequitazine. The primary endpoint of this study was the number of days without symptoms during
the 8 weeks of treatment. In addition, the Japanese Pediatric Asthma Control Program (JPAC) scores were
also recorded every 2 weeks in each group.
Results: Overall, 14 patients received suplatast, and 13 received mequitazine for 8 weeks from September
through early October. During follow-up, the number of days without symptoms and the total JPAC scores did
not differ significantly between the groups. However, as compared with weeks 1 to 2 of treatment, the mean
number of days without symptoms during weeks 7 to 8 increased significantly in only the suplatast group (8.6
vs. 11.5 days; p = 0.004).
Conclusions: Our results suggest that short-term additional treatment with suplatast is useful for preventing
asthma symptoms in children with asthma, which is usually exacerbated in the autumn.
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INTRODUCTION
Exacerbations of bronchial asthma usually occur in
the autumn.1-4 One of the reasons why asthma is ex-
acerbated is that autumn is also viral season which
leads to major exacerbations of asthma. Leukotriene
receptor antagonists have been reported to prevent
exacerbations of asthma associated with airway infec-
tions in the autumn.5 Omalizmab is also shown to pre-
vent seasonal exacerbations.6 To our knowledge,
however, the effectiveness of other types of drugs for
preventing exacerbations of asthma in the autumn
has not been studied previously. It is suggested that
suplatast tosilate is effective for antileukotriene non-
responders with asthma.7 One of the reasons of why
suplatast tosilate is effective for antileukotriene non-
responders is relationship between the benefits of
suplatast tosilate and gene polymorphisms.8,9 There-
fore, it becomes a useful option if suplatast tosilate is
effective in preventing exacerbation of asthma in the
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autumn. So, we compared the additive effectiveness
of suplatast with that of mequitazine for the preven-
tion of exacerbations of asthma in the autumn.
METHODS
This study is an open label, multicenter, randomized
Phase II study investigating prophylactic effective-
ness of suplatast tosilate with that of mequitazine in
children with asthma, which is usually exacerbated in
the autumn. As previously noted, because of the po-
tentially effect of suplatast tosilate on antileukotriene
non-responders, current study compared mequitazine
with suplatast tosilate, without comparing leukotriene
receptor antagonists, to establish its prophylactic ef-
fect on asthma exacerbated in the autumn. Suplatast
tosilate is thought to act by inhibiting cytokine pro-
duction by type 2 helper T (Th2) cells and improving
the balance between type 1 helper T (Th1) cells and
Th2 cells, thereby exerting antiallergic effects.10,11
On the other hand, mequitazine is a histamine H1 re-
ceptor antagonist (H1RA). Although H1RA doesn’t
have sufficient evidence for effectiveness against
asthma, it has been approved in Japan as a medicine
for pediatric asthma. So we used mequitazine as a
control to investigate the effect of Suplatast tosilate.
STUDY DESIGN
Children 2 to 15 years of age with bronchial asthma
were eligible in this multicenter, collaborative, con-
trolled clinical trial from September 1, 2009 through
December 31, 2009. Asthma diagnosis is based on
the Japanese Pediatric Guideline for the Treatment
and Management of Asthma 2008 (JPGL2008). Dis-
ease severity of the subjects consisted of mild persis-
tent and moderate persistent type, mild intermittent
and severe persistent type were excluded. All sub-
jects required rescue inhaled β2 stimulator to manage
asthmatic attacks during the past year and had
missed at least 1 day of school because of asthma
during the past year, or their daily activities were
markedly restricted. Patients had a history of asth-
matic attacks in the autumn of the previous year and
tested positive at least for mite allergen (capsulated
hydrophilic carrier polymer radioallergosorbent
tests). Informed consent to participate in the study
was obtained from the parents or guardians of 27 chil-
dren with asthma. The subjects were randomly as-
signed to receive either suplatast (14 patients) or
mequitazine (13 patients). In the suplatast group, pa-
tients received suplatast tosilate dry syrup (6 mgkg
day). In the mequitazine group, patients received
mequitazine (0.24 mgkgday) as pediatric syrup, pe-
diatric fine granules, or tablets. These are approved
dosages in Japan. In each group, suplatast or mequi-
tazine was administered in addition to the patients’
usual antiasthmatic medications for 8 weeks to assess
the prophylactic effect on symptoms. The numbers of
days without symptoms and the Japanese Pediatric
Asthma Control Program (JPAC) scores were re-
corded every 2 weeks in each group. The primary
endpoint was the number of days without symptoms
during the 8 weeks of treatment. The prophylactic ef-
fect on asthmatic symptoms was also compared be-
tween the groups.
STATISTICAL ANALYSIS
The primary end point was the number of days with-
out signs or symptoms of asthma (no asthmatic
symptoms, no sleep disturbances at night, and no
treatment with relievers) according to the patient’s
asthma diary. The statistical significance of differ-
ences between the suplatast group and mequitazine
group in the numbers of days without asthmatic
symptoms, JPAC scores for each variable evaluated,
and total JPAC scores was evaluated with two-sample
t-tests. Treatment effectiveness over time in each
group was compared with the use of paired t-tests.
ETHICS
This study was approved by the Regional Ethics
Committee for Human Research at Dokkyo Medical
University Hospital. Oral and written informed con-
sent was obtained from the parents or guardians of all
patients participating in this study.
JPAC SCORES
JPAC scores are designed to facilitate the long-term
management of asthma according to the Japanese Pe-
diatric Guideline for the Treatment and Management
of Asthma (JPGL), issued by the Japanese Society of
Pediatric Allergy and Clinical Immunology.12 The
scores can be used to evaluate disease severity ac-
cording to the JPGL. Patients and their guardians
were interviewed to ascertain the following variables:
1) the severity of wheezing, 2) the number of dysp-
nea episodes, 3) the frequency of night awakening, 4)
coughing and wheezing on exertion, and 5) the fre-
quency of inhalant, oral medicine, or patch use for
asthma exacerbation in the last month. Disease se-
verity (intermittent type, mild persistent type, moder-
ate persistent type, and severe persistent type) was
evaluated on the basis of the severest symptom
among interview variables 1) to 3) if the patient was
not receiving long-term maintenance therapy. If the
patient was already receiving long-term maintenance
therapy, disease severity was evaluated on the basis
of the treatment step and asthmatic symptoms during
the past month. Control status was evaluated on the
basis of the total scores for the 5 interview items,
each of which was divided into 4 levels ranging from
0 to 3. The best status was assigned a score of 3, and
the worst status was assigned a score of 0. A total
score of 15 (3 points for each of the 5 interview items)
was defined as complete control, a score 12 to 14 as
good control, and a score of 11 or lower as poor con-
trol.
Effect of Suplatast against Asthma
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Table　1　Patient background
Suplatast
(n = 14)
Mequitadine
(n = 13) P value*
Age: mean (range) 5.9 (2-12) 6.3 (2-13) 0.732
Sex: male/female 10/4 10/3 0.745
Disease severity 0.310
mild persistent type 7 9
moderate persistent type 7 4
Usual antiasthmatic medication† 0.892
Patient using combination any drug 12 (86%) 11 (85%)
Pranlukast hydrate 10 (71%) 6 (46%)
Montelukast sodium 5 (36%) 5 (38%)
Salmeterol xinafoate/fl uticasone
propionate combination inhaler
4 (29%) 3 (23%)
Budesonide 4 (29%) 2 (15%)
Sodium cromoglicate inhaler 1 ( 7%) 1 ( 8%)
Fluticasone inhaler 1 ( 7%) 0 ( 0%)
Beclomethasone (erosol) 1 ( 7%) 0 ( 0%)
Oxatomide 1 ( 7%) 0 ( 0%)
*P values for age were calculated with the use of the t-test. P values for sex, disease severity, and usual antiasthmatic medication were 
calculated with the use of the chi-square test.
†Total number of patients.
RESULTS
A total of 27 children were enrolled, and the prophy-
lactic effectiveness against asthmatic symptoms was
analyzed. The mean age of the subjects was 5.9 years
(range; 2-12 years) in the suplatast group (14 pa-
tients) and 6.3 years (range; 2-12 years) in the mequi-
tazine group (13 patients) (Table 1). Disease severity
in the suplatast group was, mild persistent type in 7,
and moderate persistent type in 7. In the mequitazine
group, disease severity was mild persistent type in 9
patients and moderate persistent type in 4. There are
not notable adverse event in the both groups. Usual
antiasthmatic medications started since diagnosis of
asthma was made. These usual medications were not
changed during the treatment period.
The primary endpoint of this study was the number
of days without symptoms during the 8 weeks of
treatment. During follow-up, the mean number of
days without symptoms during weeks 7 to 8 of treat-
ment did not differ significantly between the suplatast
group and the mequitazine group (11.5 days vs. 9.7
days; p = 0.378). However, as compared with weeks 1
to 2 of treatment, the mean number of days without
symptoms during weeks 7 to 8 increased significantly
in the suplatast group (8.6 vs. 11.5 days; p = 0.004),
but did not change in the mequitazine group (9.5 vs.
9.7 days; p = 0.811) (Fig. 1). Similarly, JPAC scores
during follow-up did not differ between the groups
(mean total JPAC scores after 8 weeks of treatment,
14.3 points in the suplatast group vs. 13.2 points in
the mequitazine group; p = 0.110) (Fig. 2). As com-
pared with 4 weeks before treatment began, however,
the mean total JPAC scores after 8 weeks of treat-
ment increased significantly in only the suplatast
group (suplatast group, 12.1 points vs. 14.3 points, p =
0.001; mequitazine group, 12.8 points vs. 13.2 points,
p = 0.420). As for the effect of treatment on individual
JPAC variables, the increase in the “coughing and
wheezing on exertion” score after 8 weeks of treat-
ment as compared with 4 weeks before treatment be-
gan was significantly greater in the suplatast group
than in the mequitazine group (suplatast group, 2.9
points vs. mequitazine group, 2.5 points; p = 0.022)
(Fig. 3). In addition, as compared with 4 weeks be-
fore treatment began, the mean “coughing and
wheezing on exertion” score after 8 weeks of treat-
ment increased significantly in only the suplatast
group (suplatast group, 2.4 vs. 2.9 points, p = 0.006;
mequitazine group, 2.4 vs. 2.5 points, p = 0.337).
DISCUSSION
On the basis of the number of days without symp-
toms and the JPAC scores, there was a trend toward
greater improvement in the mequitazine group dur-
ing the first 4 weeks of treatment (Fig. 2). Subse-
quently, however, symptoms improved considerably
in the suplatast group, and at 8 weeks, the effective-
ness of suplatast surpassed that of mequitazine.
These findings suggest that about 1 month is re-
quired for suplatast to become effective. Therefore,
when suplatast is used to prevent asthmatic attacks,
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202 Allergology International Vol 63, No2, 2014 www.jsaweb.jp
Fig.　1　Transition of asymptomatic days. The mean number of days without symptoms during weeks 7 to 8 of 
treatment did not differ signifi cantly between the suplatast group and the mequitazine group. However, as com-
pared with weeks 1 to 2 of treatment, the mean number of days without symptoms during weeks 7 to 8 increased 
signifi cantly in the suplatast group, but did not change in the mequitazine group.
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Fig.　2　Comparison of total JPAC score. As compared with 4 weeks before treatment began, the mean total 
JPAC score after 8 weeks of treatment increased signifi cantly in only the suplatast group.
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treatment should be started about 1 month before the
beginning of autumn to ensure effective prophylaxis.
We previously reported the secondary prevention
of asthma by suplatast in infants with atopic dermati-
tis caused by food allergies, considered a high risk
factor for asthma.13 Our results showed that suplatast
significantly inhibited the onset of wheezing and the
need for hospitalization due to wheezing, as com-
pared with ketotifen fumarate. We found that
suplatast had a secondary preventive effect on atopic
asthma.
Exercise-induced asthma (EIA) has been linked to
airway hyperresponsiveness and airway inflamma-
tion.14 Suplatast can improve airway hyperresponsive-
ness and airway inflammation and alleviate asthmatic
symptoms.15 In our study, the improvement in cough-
ing and wheezing on exertion was significantly
greater in the suplatast group than in the mequitazine
group. Suplatast may thus become an important treat-
ment option for exercise-induced asthma in the fu-
ture.
In our current study, children with asthma were
enrolled in the autumn for only 4 months. Therefore,
our study was not large. In addition, we evaluated re-
Effect of Suplatast against Asthma
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Fig.　3　Comparison of coughing and wheezing on exertion score. Mean “coughing and wheezing on exertion” 
score after 8 weeks of treatment increased signifi cantly between the suplatast group and the mequitazine 
group. In addition, as compared with 4 weeks before treatment began, the mean score after 8 weeks of treat-
ment increased signifi cantly in only the suplatast group.
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sponse during up to 8 weeks of treatment. Suplatast
was shown to be effective after at least 4 weeks of
treatment, but it is unclear whether the effect pla-
teaued by week 8. Further larger studies are thus
needed to determine whether long-term treatment
with suplatast for more than 8 weeks is useful for pre-
venting exacerbations of asthma.
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